Research Ethics/Article Retraction

"Blog entry originally posted on the official PLOS Blog and is cross-posted here..." -- PLOS ECR (Early Career Researcher) Community blog entry 4/21/2021.

U.S. Department of Health and Human Services, Office of Research Integrity

ICMJE (International Committee of Medical Journal Editors)

"Zotero can now help you avoid relying on retracted publications in your research by automatically checking your database and documents for works that have been retracted." Zotero provides this service in partnership with Retraction Watch.

Use the metadata tab to search for retracted literature.

"HelioBLAST is a free service provided by HelioText. The HelioBLAST text similarity engine finds text records that are similar to the submitted query...Here, your query is searched against the citations (abstract and titles) in Medline/PubMed." -- https://helioblast.heliotext.com/

Springer and Université Joseph Fourier.
Open source software to detect fake papers generated with SCIgen, Mathgen and Physgen.

A commercial subscription product. There is a limited free level at the time of this writing (2/2021) "Launched in November, Scite Reference Check scans new article PDFs for references to retracted papers, and posts both the citing and retracted papers on Twitter. It also flags when new studies cite older ones that have issued corrections, errata, withdrawals, or expressions of concern. An extension of scite.ai, a platform that monitors whether research findings are supported or contradicted by subsequent studies, Scite Reference Check keeps track of retracted papers by trawling through Crossref, PubMed, and the Retraction Watch Database."

Nature 577, 167-169 (2020) https://doi.org/10.1038/d41586-019-03959-6

"Think. Check. Submit. helps researchers identify trusted journals and publishers for their research. Through a range of tools and practical resources, this international, cross-sector initiative aims to educate researchers, promote integrity, and build trust in credible research and publications."--website

"Think. Check. Attend. provides guidelines that help researchers to differentiate between an authentic conference and the one they should avoid."--website

Contributors: David Thomas Mellor Karen Chambers Andy Collings Chris Graf Veronique Kiermer Malcolm Macleod Sowmya Swaminathan Deborah Sweet valda vinson Date created: 2019-04-30 04:07 PM 2019-04-30 21:07 UTC -- "Description: This project contains the MDAR framework (Materials Design Analysis Reporting), a checklist for authors to use, and an elaboration document with background and instructions. The project components contain data from author and editor surveys and coder data from the evaluated checklists. License: CC-By Attribution 4.0 International"

J. Ward, Rutgers University, 2017

U.S. Dept. of Justice

A list from Retraction Watch

Retraction Watch blog interview article with Caitlin Bakker (Univ. of Minnesota)

"After all, the electronic versions of about a third of retracted papers aren’t marked as retracted. Sometimes, like Napoleon, those papers return from exile to wreak havoc: They get cited as if they had never been retracted." Retraction Watch, Adam Marcus 12/13/2012

Retraction Watch blog interview article with Gali Halevi

"Famous cases of research fraud typically involve fabricated or falsified data, but the most common form of laboratory misconduct today involves scientists publishing microscopic images that don’t match original data — so-called image manipulation. The practice likely accounts for more than 70% of cases handled by the United States Office of Research Integrity (ORI), according to Susan Garfinkel, director of the office’s Division of Investigative Oversight." -- Shuchman M. (2016). False images top form of scientific misconduct. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 188(9), 645. https://doi.org/10.1503/cmaj.109-5241

" U.S. automotive component maker Joyson Safety Systems' (JSS) Japan unit says that it has found 1,000 cases of data falsification in seatbelt tests at two plants it acquired from former airbag maker Takata Corp." -- Japantoday.com, 6/20/21

ScienceMag.org, By Cathleen O’Grady, 3/16/2021
The name Camille Noûs "intentionally added to papers, sometimes without the knowledge of journal editors—is meant to personify collective efforts in science and to protest individualism, according to RogueESR, a French research advocacy group that dreamed up the character." -- doi:10.1126/science.abi5504

Sciencemag.org post by Hristio Boytchev, 4/8/2021
Hans-Ulrich Wittchen has "almost 1000 articles to his name, according to the Web of Science, and has racked up nearly 70,000 citations." -- doi:10.1126/science.abi8979

University of California San Francisco, Weill Institute for Neuro sciences Memory and Aging Center. (2021). Aducanumab. Memory and Aging Center. https://memory.ucsf.edu/aducanumab.

Dunn B, Stein P, Cavazzoni P. Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective. JAMA Intern Med. Published online July 13, 2021. doi:10.1001/jamainternmed.2021.4607

Herman, B. (2021, July 27). Biogen pulled aduhelm paper After JAMA demanded edits. Axios. https://www.axios.com/biogen-jama-aduhelm-clinical-trial-results-publish-fc7c2876-a684-4bfc-8462-4165f57d735a.html.

Mullard, A. (2021). Controversial Alzheimer’s drug approval could affect other diseases. Nature, 595(7866), 162–163. https://doi.org/10.1038/d41586-021-01763-9

Rosenbaum, L. (2021, July 9). FDA Commissioner calls FOR Inspector GENERAL probe into Biogen Alzheimer's drug approval. Forbes. https://www.forbes.com/sites/leahrosenbaum/2021/07/09/fda-commissioner-calls-for-inspector-general-probe-into-biogen-alzheimers-drug-approval/?sh=7acbcdbd3d47.

Herman, B. (2021, June 4). Alzheimer's drug decision to TEST FDA's rigor. Axios. https://www.axios.com/fda-aducanumab-biogen-alzheimers-drug-approval-3b148700-97fc-417c-9b75-42ea8e368728.html.

McGinley, L. (2021, June 22). FDA releases fresh details on internal debate over controversial Alzheimer’s drug. Washington Post. https://www.washingtonpost.com/health/2021/06/22/aducanumab-aduhelm-alzheimers-drug-controversy-/.

Herman, B. (2021, June 22). New memos show how top FDA officials THOUGHT slim evidence was enough for Alzheimer drug approval. Axios. https://www.axios.com/fda-memos-aduhelm-biogen-aducanumab-amyloid-a874892b-82ad-49b2-a37f-dacda224c777.html.